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Abstract
Dizziness and vertigo are common complaints, with a lifetime prevalence of over 30%. This review
provides a brief summary of the recent diagnostic and therapeutic advances in the field of neuro-
otology. A special focus is placed on the clinical usefulness of vestibular tests. While these have
markedly improved over the years, treatment options for vestibular disorders still remain limited.
Available therapies for selected vestibular diseases are discussed.
Introduction and context
Dizziness and vertigo are common complaints. Recently,
Neuhauser et al. published two papers that reported a
one year prevalence of 20% and a one year incidence of
3% for dizziness and vertigo in a general population,
with reported cases higher in women than men [1,2].
Moreover, the impact of dizziness on social and working
life is considerable [3]. Half of the patients affected by
dizziness feel that their efficiency at work has substan-
tially dropped and one-quarter of patients even give up
or change their work as a result of dizziness [3]. Here we
aim to provide an overview on recent advances in the
diagnosis and therapy of vestibular disorders.
Assessment of semicircular canal function
Since the invention of the caloric test by Bárány about
100 years ago [4], caloric irrigation and rotatory chair
tests were the primary methods used to investigate
semicircular canal (SCC) function up until the end of the
last century. These tests, however, have poor reliability,
mainly due to the following disadvantages: caloric
irrigation (i.e., the thermal gradient across the inner
ear) depends on anatomical factors of the middle ear,
temporal bone thickness, and on the technician’s skills,
and conventional rotatory chairs deliver rather low-
testing stimuli (usually <100 deg/s peak velocity and
between 0.1 and 2 Hz frequency) [5,6]. Both methods,
moreover, are almost exclusively used for investigating
the horizontal SCC. In 1988, Halmagyi and Curthoys [7]
introduced a new diagnostic method known as the head
impulse test (HIT), which has the significant advantage
of assessing the function of an individual SCC. It can be
performed at the bedside and has been shown to have a
high sensitivity (~70%) and specificity (~70%) for
detecting horizontal peripheral vestibular hypofunction
even when conducted by physicians that do not
specialize in neuro-otology [8]. In contrast to the caloric
irrigation and rotatory chair tests, the quantitative
measurement of HIT performed by the dual search-coil
method is technically complex and expensive and thus
only available in tertiary referral centers, despite allowing
functional testing of all six individual canals [9].
Direct comparison of the diagnostic utility of caloric
irrigation, rotatory chair testing, and HIT is problematic,
as these three methods probe different frequency ranges
of vestibular function. In Ménière’s disease, for example,
it has been shown that low-frequency vestibular function
as assessed by caloric irrigation is affected earlier than
high-frequency vestibular function as investigated by
HIT [10]. The opposite is observed in Fabry disease, a
congenital lysosomal storage disease [11]. These differ-
ences possibly result from the affection of different types
of hair cells on the cupula. Moreover, in vestibular
neuritis (a sudden unilateral deficit of the peripheral
vestibular organ), recovery of vestibular imbalance is
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frequency dependent: while the low-frequency vestibular
function determined by caloric irrigation becomes
symmetrical, the high-frequency function assessed by
HIT often remains impaired [12,13].
Assessment of otolithic function
Estimation of the subjective visual vertical (SVV) is a
simple method to assess utricular otolith function. In
general, it is performed with the subject sitting upright
in a stationary position in darkness and adjusting a
luminous line to match the perceived earth-vertical. SVV
estimation might be normal in a patient with chronic
unilateral peripheral utricular hypofunction tested in a
stationary position, however, deficits may be unmasked
during eccentric rotation or by off-vertical axis rotation
(OVAR) because any utricular otolith function asymme-
try will be enhanced, thereby increasing the likelihood
of detection. Rotational testing, however, is technically
demanding and OVAR can induce motion sickness. This
explains why both tests have been applied relatively
seldomly to patients.
Recent advances
Diagnosis
In recent years there have been major advances in the
methods used to diagnose vestibular organ function,
allowing much better and easier diagnosis in dizzy
patients. Some of these advances have been outlined
below.
Assessment of semicircular canal function
To allow a quantitative measurement of HIT in clinical
practice, new testing methods like the Video-HIT [14-16]
and the dynamic visual acuity (DVA) test [17-20] are in
the process of development. The DVA test is an easy,
accessible, and low-cost method. With the recent
improvement of DVA test parameters [21], sensitivity
and specificity for unilateral and bilateral vestibular loss
have significantly increased to 100% and 94%, respec-
tively, in comparison with the search-coil method to
quantitatively assess HIT. A major disadvantage of the
DVA test, however, is that it depends on the cooperation
of the patient; if the patient is unwilling or unable to
cooperate, the test cannot be evaluated. In contrast, Video-
HIT is much less dependent on patient cooperation and
has been shown to be equivalent to the search-coil
method in detecting peripheral vestibular deficits [15].
Assessment of otolithic function
Click vestibular-evoked myogenic potentials (VEMPs)
are saccular otolith-mediated short-latency reflexes
recorded by electromyography from the ipsilateral
sternocleidomastoid muscle in response to intense
auditory clicks [22]. VEMPs are technically easy to
perform and have been helpful in the diagnosis of a
relatively new vestibular entity, the superior canal
dehiscence syndrome (SCDS) [23]. One should be
aware of this entity in patients with chronic disequili-
brium of unknown origin. The etiology is still unclear
but there is evidence that it could be due to a
developmental abnormality [24,25]. Recently, a simple
method using ocular VEMPs (oVEMPs) to measure the
utricular function was introduced [26]. The method
measures potentials in the inferior oblique muscle,
which are mainly caused by stimulation of the contral-
ateral utricle. This method is at least as good at detecting
utricular deficits as the SVV during eccentric rotation
[27]. It also shows significant differences between
controls and SCDS patients. [28]. Due to the aforemen-
tioned benefits, this method may lead to a better
knowledge of the long-lasting effects of utricular lesions
in patients. A recent study found chronic symptoms
associated with isolated unilateral utricular deficit [29]
although measured with the older method of eccentric
rotation. According to this study, the current view that a
unilateral otolithic lesion can cause only short-lasting
symptoms may have to be changed. OVAR is another
possibility to measure utricular function [30] but it is
technically complex and almost always nauseogenic
[31]. Overall, oVEMPs are definitely cheaper, technically
easier, and less demanding for patients and investigators.
Treatment
Treatments of peripheral vestibular disorders
In patients with acute vestibular neuritis, treatment with
methylprednisolone has been shown to significantly
improve vestibular recovery [32]. Interestingly, treatment
with methylprednisolone plus valacyclovir was not
superior to treatment with methylprednisolone alone.
It is surprising that the antiviral drug valacyclovir did not
improve the outcome of vestibular neuritis, since the
underlying etiology is thought to be viral. One possible
reason might be that medication was initiated within
3 days after symptom onset during which viral replica-
tion could have already occurred.
Recently, a non-blinded, non-placebo controlled study
of patients with Ménière’s disease demonstrated the
superiority of high-dose betahistine (48 mg three times
daily) over low-dose betahistine (16-24 mg three times
daily) [33]. Intratympanic steroid injection is another
promising treatment for Ménière’s disease, as suggested
by several studies [34,35]; most of these, however, were
not placebo-controlled either [34,35]. To date, it is still
unclear what type of steroids for intratympanic inject-
ion are most effective, how often injections must be
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repeated, and which time interval between injections is
optimal.
While gentamicin is effective for reducing vertigo attacks
in Ménière’s disease [35], very recently it has also been
shown to increase postural control after vestibular
schwannoma resection in patients with preserved partial
vestibular function treated with gentamicin and vestib-
ular physical therapy before surgery (compared to
physical therapy alone) [36,37]. Although only a
relatively small number of patients were enrolled in
these studies, these results suggest that patients with
pre-operative gentamicin treatment might benefit in
terms of faster vestibular recovery and/or central
compensation.
Treatments of central vestibular diseases
Treatment of vestibular migraine often parallels that of
migraine headache but, to date, no large randomized
placebo-controlled studies looking into effective treat-
ments for this condition exist [38]. This shortcoming is
probably due to the lack of commonly-used diagnostic
criteria for vestibular migraine.
Several retrospective and case studies have suggested
that prophylaxis beta-blockers (metoprolol, proprano-
lol) [39,40], tricyclic antidepressants (amitriptylin,
nortriptyline) [41], the calcium antagonist flunarazine
[39], the serotonin antagonist pizotifen [41,42], and the
carboanhydrase inhibitor acetazolamid [43] may be
effective in the treatment of vestibular migraine. For
treatment of acute vestibular migraine, triptans [44,45]
and vestibular suppressants [44] have been reported to
be beneficial.
Recent advances have been made in the pharmacother-
apy of central vestibular nystagmus. Aminopyridine is
a promising treatment option, especially for downbeat
nystagmus (DBN). In animal experiments, 4-amino-
pyridine (4-AP) has been shown to increase the
excitability of cerebellar Purkinje cells [46]. A similar
mechanism of 4-AP action is postulated in humans
[47]. In patients with cerebellar diseases, 4-AP and
3,4-diaminopyridine (3,4-DAP), a related agent with
similar pharmacologic effects, have been shown to
effectively suppress DBN [48-49]. Moreover, 4-AP
improves smooth pursuit eye movements and the
gain of the vestibulo-ocular reflex function, and
restores gaze-holding abilities [48,49], while 3,4-DAP
reduces the gravity-dependent component of DBN
[51,52] and improves postural stability [53]. Further-
more, in patients with episodic ataxia type 2, 4-AP can
reduce the frequency of ataxic episodes [54].
Implications for clinical practice
Vestibular function assessment
The implementation of the Video-HIT and DVA makes
quantitative assessment of peripheral vestibular semi-
circular canal function now possible in any clinical
setting. Not only do Video-HIT and DVA help clinicians
to diagnose a peripheral vestibular deficit, but they also
assist in monitoring vestibular recovery, such as after
vestibular neuritis.
VEMP should be performed whenever SCDS, a perilym-
phatic fistula, or a large vestibular aqueduct syndrome is
suspected [55,56]. Typical VEMP responses in patients
with these conditions show increased amplitudes and
lowered thresholds compared with normal control
subjects [57]. VEMPs can also be used to differentiate
superior vestibular neuritis (i.e., the affection of the
superior division of the vestibular nerve) from a total or
inferior vestibular neuritis (i.e., the affection of the
inferior division of the vestibular nerve), since in the
former the saccular function is mostly spared and, thus,
VEMP responses are normal. It has not yet been shown
whether the little part of the sacculus being innervated by
the superior vestibular nerve has a significant effect on
the VEMP in superior vestibular neuritis.
Treatments of peripheral vestibular disorders
Clinicians are advised to initiate drug therapy in patients
with vestibular neuritis with methylprednisolone (e.g.,
100 mg/day for 7 days) within 1 week (or maybe even
up to 4 weeks) after the onset of symptoms. The time of
treatment onset for corticoid administration has not
yet been studied and whether an increased dose (e.g.,
250 mg/day instead of 100 mg/day methylpredisone)
has a better effect is a matter of debate. In patients
severely affected by vestibular neuritis, clinicians might
consider the administration of valacyclovir (1000 mg
three times a day for 7 days) if diagnosis is made within
3 days of symptom onset.
Since intratympanic steroid injections reach a higher
level in the inner ear fluids than oral or intravenous
administrations, this application technique may have a
better effect in acute vestibulopathies. However, vestib-
ular disorders are often thought of as being the result of
nerve damage (neuritis), and it would be unlikely that
the nerves would be reached by intracochlear steroids.
No studies about intratympanic treatment exist, so this
point has not yet been validated.
When treating Ménière’s disease, intratympanic steroid
injections are appropriate if the disease does not respond
to conventional medical treatment with betahistine and
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cinnarizine, and should be considered before more
invasive and vestibulotoxic interventions like intratym-
panic gentamicin injections or surgery.
Treatments of central vestibular diseases
When treating vestibular migraine, clinicians are advised
to closely follow the treatments proposed by Neuhauser
and Lempert [58] and are recommended to read a recent
review by Lempert et al. on vertigo as a symptom of
migraine [59]. Those making decisions about drug
selection for the treatment of vestibular migraine should
also consider potential side-effects, such as increased
depression with flunarazine treatment or orthostatic
hypotension with beta-blockers. A 50% reduction of
attacks is a reasonable goal to aspire to [60]. It is advised
that patients monitor the severity and frequency of
attacks on a calendar and that the efficacy of drugs be
evaluated after 3 months. Moreover, lifestyle modifica-
tions approved for migraine prophylaxis (e.g., regular
exercise, sleep, and diet) should be discussed.
Finally, it has to be emphasized that from what is known
so far, aminopyridine seems to be effective predomi-
nantly in patients with cerebellar atrophy and with DBN
of an unknown etiology, and less effective in patients
with structural cerebellar lesions [48,50,61].
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